Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

36.23 -0.85 (-2.29%)
Streaming Delayed Price Updated: 10:03 AM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
28 29 Next >
News headline image
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum ↗
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk. 
Via Benzinga
News headline image
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow ↗
Via The Motley Fool
News headline image
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs ↗
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
News headline image
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
How Is The Market Feeling About Viking Therapeutics? ↗
 
Via Benzinga
News headline image
Is It Too Late to Buy Viking Therapeutics Stock? ↗
Via The Motley Fool
News headline image
Market Whales and Their Recent Bets on VKTX Options ↗
 
Via Benzinga
News headline image
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
News headline image
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs ↗
Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement. 
Via Benzinga
News headline image
Money In Motion: Top Picks To Power Your Portfolio Today ↗
Top stocks set to dominate the market today. 
Via Talk Markets
News headline image
3 Things You Need to Know if You Buy Viking Therapeutics Today ↗
Via The Motley Fool
News headline image
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. ↗
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
News headline image
Unpacking the Latest Options Trading Trends in Viking Therapeutics ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? ↗
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry. 
Via The Motley Fool
News headline image
Is Viking Therapeutics a Buy on the Dip? ↗
Viking stock has slipped more than 20% from its peak. 
Via The Motley Fool
News headline image
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
News headline image
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move ↗
All signs are pointing toward its continued success. 
Via The Motley Fool
News headline image
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag ↗
The company's latest presentation supports the idea that its lead program will make billions. 
Via The Motley Fool
News headline image
Is Viking Therepautics a Buy Now? ↗
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Plummeted After Soaring Today ↗
Are we ready for the Great Obesity Drug Gold Rush of the 2020s? 
Via The Motley Fool
News headline image
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety ↗
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes. 
Via Benzinga
News headline image
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data ↗
The biotech reported strong weight loss for higher doses of its experimental obesity pill. 
Via Investor's Business Daily
News headline image
MarketBeat Week in Review – 10/28 - 11/1
Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
News headline image
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors 
Via MarketBeat
News headline image
This High-Flying Stock Just Became a Better Buy ↗
It might not be too late to get in on the party. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.